Evolution Wealth Advisors’s NanoViricides NNVC Stock Holding History

Evolution Wealth Advisors’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-500	Closed	-$2K	–	614
2020 Q3	$2K	Hold	500	–	–	﹤0.01%	550
2020 Q2	$4K	Hold	500	–	–	﹤0.01%	397
2020 Q1	$3K	Buy	+500	New	+$3.53K	﹤0.01%	287

Other funds holding NNVC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Evolution Wealth Advisors's NNVC Position: Q4 2020 in Review

Evolution Wealth Advisors sold out of NanoViricides (NNVC) in Q4 2020, closing a stake of 500 shares — an estimated $2K sold.

Evolution Wealth Advisors first reported a position in NNVC in Q1 2020 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 29 funds tracked by Wall St. Rank hold NNVC as of Q4 2020.

Evolution Wealth Advisors reported no remaining NanoViricides position as of Q4 2020 after selling out during the quarter.
Evolution Wealth Advisors sold 500 NanoViricides shares in Q4 2020, an estimated $2K.
Evolution Wealth Advisors first reported a position in NanoViricides in Q1 2020 and held it in 3 quarters.
Evolution Wealth Advisors's NanoViricides position peaked at $4K in Q2 2020.
29 funds tracked by Wall St. Rank held NanoViricides as of Q4 2020.

Based on Evolution Wealth Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.